Medicus Pharma Advances SkinJect Toward Registrational Trial for Rare Gorlin Syndrome

Why It Matters

A successful registrational trial would give Medicus the first approved therapy for Gorlin syndrome, delivering orphan‑drug exclusivity and a potential FDA voucher, while the new capital ensures sustained development without dilution.

Key Takeaways

• Medicus files FDA registration study for SkinJect in Gorlin syndrome.
• Phase‑2 data shows clean dose‑response, supporting partnership talks.
• Orphan drug designation grants seven‑year exclusivity and fee waiver.
• $22 million investment lifts cash runway to over 24 months.
• Pediatric rare‑disease designation could earn FDA voucher for future deals.

Summary

Medicus Pharma announced that it has filed an FDA‑sponsored registration study to evaluate its non‑invasive SkinJect patch in patients with Gorlin syndrome, a rare autosomal‑dominant condition characterized by multiple basal‑cell carcinomas. The study will enroll roughly 50 patients on a visual‑clearance endpoint, positioning the company to seek a New Drug Application if results are positive.

The company highlighted clean, dose‑responsive Phase‑2 data that underpin its partnership strategy with larger pharmaceutical players. An orphan‑drug designation already secured seven‑year market exclusivity and a $5 million filing‑fee waiver, while a pediatric rare‑disease designation could unlock an FDA rare‑disease voucher.

CEO Dr. Raza Bokhari emphasized that Gorlin patients currently lack any approved therapy, calling the filing a “paradigm shift” for the SkinJect program. He also noted a recent $22 million institutional investment that lifts cash on hand to about $30 million, extending the runway beyond two years without dilutive financing.

If the trial meets its endpoints, Medicus could commercialize the first FDA‑cleared treatment for Gorlin syndrome, creating a high‑margin niche and enhancing its bargaining power in future partnership or acquisition talks.

Original Description

Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive to announce a significant regulatory milestone for the company’s SkinJect® program, revealing that Protocol SKNJCT-005 has been submitted to the U.S. Food and Drug Administration under the company’s existing Investigational New Drug (IND) application. The submission is designed to advance SkinJect® into registrational-stage development for patients suffering from Gorlin Syndrome, a rare inherited genetic disorder characterized by the lifelong development of multiple basal cell carcinomas and recurrent skin cancers.

Bokhari explained that the filing represents an important step in expanding the clinical development strategy for SkinJect® into an orphan disease indication with substantial unmet medical need. The company believes Gorlin Syndrome presents a compelling opportunity because current treatment options remain limited and there are no FDA-approved lesion-directed therapies specifically developed for patients living with the condition.

Gorlin Syndrome is a rare autosomal dominant genetic disorder most commonly caused by mutations affecting the Hedgehog signaling pathway. Individuals diagnosed with the disorder may develop dozens, hundreds, or in some cases more than a thousand skin cancer lesions over their lifetime, requiring ongoing medical intervention and repeated surgical procedures.

According to Bokhari, the chronic nature of the disease creates a significant burden on patients, caregivers, and healthcare systems. Repeated surgeries and treatments can lead to scarring, disfigurement, and reduced quality of life, highlighting the need for alternative treatment approaches capable of addressing individual lesions in a more targeted and patient-friendly manner.

The company is also pursuing Orphan Drug Designation for the indication, which could provide several important regulatory and commercial benefits if granted by the FDA. These incentives include exemption from FDA new drug application fees, which currently exceed $5 million, as well as seven years of market exclusivity in the United States following regulatory approval.

#proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #SkinJect #ClinicalTrials #Phase2 #Biotech #Dermatology #SkinCancer #BasalCellCarcinoma #Microneedle #DrugDelivery #GorlinSyndrome #RareDisease #OrphanDrug #Biotech #SkinCancer #ClinicalTrials #DrugDevelopment #HealthcareInnovation